Clinical-stage biopharmaceutical venture OmRx Oncology (OmRx) has commenced a randomised Phase II clinical trial for its oral ...

BeiGene has announced that its Tevimbra (tislelizumab) has been approved by the European Commission (EC) as part of a ...

A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings, published ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from ...

A community bowling fundraiser is raising money to help a local man cover cancer treatment and travel expenses.

Predictors of longer postdiscontinuation progression-free survival include complete/partial response, longer treatment duration.

Raymond Osarogiagbon, MD, discusses innovative strategies for improving lung cancer screening, including artificial intelligence (AI) tools and simplified eligibility criteria.

Targeting clonal antigens and circumventing dysfunctional states may be important for conferring clinical responses to TIL therapy.

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...

Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop ...